Leadership

Our Vision and Mission

iCAD is a global leader in medical technology providing innovative cancer detection and therapy solutions. Through passionate ingenuity, iCAD delivers transformative innovations to precisely and effectively predict, detect and treat cancer earlier, empowering clinicians to provide quality, cost-effective patient care.

 

Our transformative technologies are proven to improve patient outcomes with increased accuracy and efficiency. Our commitment to advancing access to our cutting-edge solutions is driven by the valuable benefits they offer to physicians, facilities, and patients worldwide.

 “iCAD’s technologies offer clinical performance superiority, workflow improvements, and a broad healthcare economic value proposition for both clinicians and patients. We are enhancing patient care and optimizing outcomes, which ultimately translates to improving, extending, and saving lives. I look forward to working with our talented and passionate team to advance the Company as we continue to evolve our business and technology, drive sustained market leadership, and create additional significant shareholder value.”

— Stacey Stevens - President and CEO

Our Leadership

Stacey Stevens
President and CEO
| LinkedIn
Stephen P. Sarno
Interim Chief Financial Officer
| LinkedIn
Jonathan Go
Chief Technology Officer
| LinkedIn

Our Board of Directors

Timothy Norris Irish
Chairman
Professor at the Business School at King’s College London (KCL)
| LinkedIn
Dana Brown
Strategic Advisor,
Susan G. Komen
®
| LinkedIn
Nathaniel Dalton
Co-Founder and Chief Executive Officer of Sora Union
| LinkedIn
Dr. Rakesh Patel
Chief Executive Officer,
Precision Cancer Care Specialists Medical Group
| LinkedIn
Andrew H. Sassine
Chief Financial Officer,
Arcturus Therapeutics
| LinkedIn
Stacey Stevens
President and CEO
| LinkedIn
Susan Wood, Ph.D.
Chief Executive Officer,
VIDA Diagnostics
| LinkedIn

Medical Advisory Board

Emily F. Conant, MD, FSBI
Division Chief, Breast Imaging
Vice Chair Faculty Development, Professor of Radiology at the Hospital of the University of Pennsylvania, Perelman School of Medicine
| LinkedIn
Stamatia Destounis MD, FACR, FSBI, FAIUM
Partner Radiologist, Elizabeth Wende Breast Care,
Clinical Professor University of Rochester Imaging Sciences
| LinkedIn
Per Hall, MD, PhD
Professor at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| LinkedIn
Linda Moy, MD, FISMRM, FSBI
Professor of Radiology, NYU Grossman School of Medicine, Center for Advanced Imaging Innovation and Research, Faculty, Vilcek Institute of Graduate Biomedical Sciences, Laura and Isaac Perlmutter Cancer Center
| LinkedIn
Robert Nishikawa, PhD, FAAPM, FSBI, FAIMBE
Professor of Radiology at the University of Pittsburgh, Director of Imaging Research Laboratory
| LinkedIn
Kathy Schilling, MD
Medical Director of Christine E. Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital, Affiliate Assistant Professor of Clinical Biomedical Science, Florida Atlantic University, Charles E Schmidt College of Medicine
| LinkedIn

A medical technology leader providing innovative cancer detection and therapy solutions worldwide

Contact UsInvestorsPartners

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon

 “iCAD’s technologies offer clinical performance superiority, workflow improvements, and a broad healthcare economic value proposition for both clinicians and patients. We are enhancing patient care and optimizing outcomes, which ultimately translates to improving, extending, and saving lives. I look forward to working with our talented and passionate team to advance the Company as we continue to evolve our business and technology, drive sustained market leadership, and create additional significant shareholder value.”

— Stacey Stevens - President and CEO